Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart failure patients. Mesoblast shares jumped 13.4% to $2.4399 on Monday.
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 100 points on Wednesday. The Dow traded up 0.20% to 38,662.69 while the NASDAQ rose 0.64% to 16,041.08. The S&P 500 also rose, gaining, 0.53% to 5,105.72.
TRxADE Health said the special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the company's web-based market platform assets and is payable to stockholders of record as of March 18 with the dividend being paid on or about March 22.
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Wednesday. The Dow traded up 0.62% to 38,825.33 while the NASDAQ rose 0.81% to 16,069.34. The S&P 500 also rose, gaining, 0.80% to 5,119.15.
